Loading clinical trials...

Conjunctival Allergen Challenge (CAC) Following Allergen Exposure in the Allergen BioCube (ABC) | Clinical Trials | Clareo Health

COMPLETED

Conjunctival Allergen Challenge (CAC) Following Allergen Exposure in the Allergen BioCube (ABC)

A Pilot Study Evaluating the Effect of Conjunctival Allergen Challenge (CAC) on Nasal and Ocular Allergic Symptoms Following Allergen Exposure in the Allergen BioCube (ABC) in Subjects With Seasonal Allergic Rhinoconjunctivitis

NCT00985296•ORA, Inc.

View on ClinicalTrials.gov

Summary

To evaluate the effect of Conjunctival Allergen Challenge (CAC) with Dust Mites on nasal and ocular allergic symptoms following allergen exposure in the Allergen BioCube (ABC).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•be at least 18 years of age;
•if female, cannot be pregnant or nursing;
•have a history of ocular and nasal allergy;
•have a positive skin test reaction to ragweed within the past 24 months;
•may/may not have a positive skin test reaction to dust mites within the past 24 months

Exclusion Criteria

•have a history of mild persistent, moderate or severe asthma within the preceding 5 years according to the National Heart, Blood and Lung Institute classification;
•have a compromised lung function;
•have any ocular condition that could affect the subject's health or the study parameters;
•have any presence of active ocular or sinus infection;
•have significant nasal conditions;
•have any significant illness that could be expected to interfere with the subject's health or with the study parameters;
•use specified disallowed medications (topical, topical ophthalmic, systemic and/or injectable treatments and all anti-allergy therapies) during the study or appropriate pre-study washout period;
•have used an investigational drug or device within 30 days of starting the study or be concurrently enrolled in another investigational drug or device study within 30 days of the study;

Locations (1)

ORA, Inc.

Andover, Massachusetts, United States

Key Dates

Start Date

September 1, 2009

Primary Completion Date

August 1, 2010

Completion Date

August 1, 2010

Last Updated

September 21, 2010

Enrollment

120

ESTIMATED participants

Conditions

Allergic Rhinoconjunctivitis

Evaluation of the Efficacy of Allergen-specific Immunotherapy Using Assessment in an Allergen Exposure chamber-a Randomized Placebo-controlled Double-blind Study

NCT06778213

Allergic Rhinoconjunctivitis

View study

COMPLETEDPHASE2

Study of BLU-808 in Allergic Rhinoconjunctivitis

NCT06922448

Allergic Rhinoconjunctivitis

View study

COMPLETEDPHASE2

Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction

NCT04502966

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 21, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Conjunctival Allergen Challenge (CAC) Following Allergen Exposure in the Allergen BioCube (ABC)

Inclusion Criteria

Exclusion Criteria

Evaluation of the Efficacy of Allergen-specific Immunotherapy Using Assessment in an Allergen Exposure chamber-a Randomized Placebo-controlled Double-blind Study

Study of BLU-808 in Allergic Rhinoconjunctivitis

Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction

Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis

Efficacy and Safety of Norketotifen in Adults With Allergic Rhinitis

Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy